Health ❯ Healthcare ❯ Pharmaceuticals

Medications

GLP-1 Drugs Semaglutide Weight Loss GLP-1 Receptor Agonists Tirzepatide Wegovy Obesity Treatments Weight Loss Drugs Alzheimer's Disease Statins

UK Regulator Approves Eli Lilly’s Foundayo Tablet for Weight Loss and Type 2 Diabetes

The MHRA’s authorisation allows private prescriptions now, with NHS funding subject to a NICE cost‑effectiveness review.

FDA Approves Orzeyful as First Orexin Agonist for Narcolepsy Type 1

Retailers Move to Fill $50 Medicare GLP‑1 Prescriptions

Anvisa Registers Five New Semaglutide Pens

NHS to Offer Fampridine to Thousands With Multiple Sclerosis

Novartis Returns to Sales Growth as New Drugs Offset Entresto Slump

FDA Approves Lipfendra, First Oral PCSK9 Pill for High LDL Cholesterol

FDA Approves Lipfendra, First Oral PCSK9 Pill to Lower LDL Cholesterol

FDA Approves First Oral PCSK9 Pill, Merck’s Lipfendra

FDA Approves Lipfendra, First Oral PCSK9 Pill to Lower LDL

Purified THC‑CBD Drug Cuts Agitation in End‑of‑Life Dementia, Trial Shows

Wegovy Pill Hits UK Private Market as Safety and Access Worries Rise

Brazilian-Made Semaglutide Pen Ozivy Now on Sale

Employers and Insurers Pull Back Coverage for GLP‑1 Weight‑Loss Drugs

Large Observational Studies Link GLP‑1 Drugs to Lower Cancer Rates and Slower Progression

EMS’s Ozivy Cleared by Anvisa as First Synthetic Semaglutide Pen After Patent Expiry

Anvisa Registers Ozivy as Brazil’s First Synthetic Semaglutide Analogue

Novo Nordisk Cuts Ozempic Price for Uninsured Canadians as Generics Hit Shelves

Anvisa Halts Specific Lots of Cimed Statins and Hypofarma Dexamethasone

Canada Expands Access to Semaglutide With Home Delivery and First G7 Generics